RCT low-risk patients in Thailand comparing HCQ, darunavir/ritonavir, and zinc, with ivermectin and zinc, showing no significant differences. All patients recovered. 65% of patients were asymptomatic at baseline, 26% were PCR- at baseline, and 84% were culture negative at baseline. The percentage of patients symptomatic at baseline was 15% higher for ivermectin.
The reported trial id NCT02045069 (history)
is a 2014 dengue trial with a status of recruiting [clinicaltrials.gov]
. Authors claim both treatments had no clinical benefit, however all patients were discharged from quarantine as planned between 10-14 days, and there was no control group. Authors claim there was "no clear evidence of antiviral effects for the control arm", however there was no control arm. Authors indicate that all patients were discharged within 14 days, however they report that one patient had Ct 22.11 at day 12.
Nimitvilai et al., 6/29/2022, Randomized Controlled Trial, Thailand, peer-reviewed, 10 authors, study period December 2020 - April 2021, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with darunavir/ritonavir and zinc sulfate) - results of individual treatments may vary, trial NCT02045069 (history)